A convenient route to new pyrrolo[1,2-c]pyrimidone, thiazolo[3,4-c]pyrimidone and pyrimido[4,5-d]pyriadazine derivatives

Article abstract of DOI:10.3987/COM-08-11562

The utility of versatile, readily accessible ethyl 6-bromomethyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (3) and ethyl 6-bromomethyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (4) in the synthesis of some new pyrimidine, pyrimido[4,5-d]pyridazine, pyrrolo[1,2-c]pyrimidone and thiazolo[3,4-c]pyrimidone derivatives is reported.

Full text of DOI:10.3987/COM-08-11562

HETEROCYCLES, Vol. 78, No. 4, 2009
937
HETEROCYCLES, Vol. 78, No. 4, 2009, pp. 937 - 946. © The Japan Institute of Heterocyclic Chemistry
Received, 28th September, 2008, Accepted, 27th November, 2008, Published online, 1st December, 2008
DOI: 10.3987/COM-08-11562
A CONVENIENT ROUTE TO NEW PYRROLO[1,2-c]PYRIMIDONE,
THIAZOLO[3,4-c]PYRIMIDONE AND PYRIMIDO[4,5-d]PYRIDAZINE
DERIVATIVES
Nabila A. Kheder, 1 Yahia N. Mabkhot, 2 and Ahmad M. Farag1 ,*
1Department of Chemistry, Faculty of Science, Cairo University, Giza 12613,
Egypt.2Department of Chemistry, Faculty of Science, King Saud University, 2455,
Riyadh 11751, Saudi Arabia
* Corresponding author: E-mail: afarag49@yahoo.com
Abstract – The utility of versatile, readily accessible ethyl 6-bromomethyl-2-
oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (3) and ethyl 6-
bromomethyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (4) in the
synthesis of some new pyrimidine, pyrimido[4,5-d]pyridazine, pyrrolo[1,2-
c]pyrimidone and thiazolo[3,4-c]pyrimidone derivatives is reported.
INTRODUCTION
Multifunctionalized dihydropyrimidine derivatives represent heterocyclic systems of remarkable
pharmacological efficiency. A broad range of medicinal effects, including antiviral,
antitumor, antibacterial, and antiinflammatory activities has been ascribed to these partly reduced
pyrimidine derivatives.1 On the other hand, several pyrrolo[l,2-c]pyrimidine compounds have been found
to be useful as pharmaceutically interesting compounds.2 Also, pyrimido[4,5-d]pyrimidine derivatives are
useful as bronchodilators3 and are used as antifungal4 and for treatment of tumor diseases.5
Encouraged by these findings and in continuation of our previous work aimed at the synthesis of a variety
of heterocyclic systems for biological and pharmacological evaluation,6-18 we have found that
6-bromomethylpyrimidine derivatives 319 and 4 are a versatile, readily accessible building blocks for the
synthesis of new pyrrolo[1,2-c]pyrimidone, thiazolo[3,4-c]pyrimidone and pyrimido[4,5-d]pyridazine
derivatives of expected biological importance.
RESULTS AND DISCUSSION
The versatile synthons ethyl 6-(bromomethyl)-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate
(3)19 and ethyl 6-(bromomethyl)-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (4), were obtained

938
HETEROCYCLES, Vol. 78, No. 4, 2009
from bromination of ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1),20 and
ethyl 6-methyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (2)21 in acetic acid.
Treatment of 6-bromomethylpyrimidine
3
with sodium benzenesulfinate afforded ethyl
2-oxo-4-phenyl-6-(phenylsulfonylmethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (5) (Scheme 1).
The IR spectrum of the pyrimidine derivative 5 exhibited absorption bands at 1647, 1705, 3113 and 3337
cm-1 corresponding to two carbonyl groups, and two imino functions, respectively. Its 1H NMR spectrum
revealed a triplet signal at δ 1.00 (J = 7.5 Hz) due to CH3 protons, a quartet signal at δ 3.73 (J = 7.5 Hz)
due to CH2 protons, two singlet signal at δ 4.94 and 5.12 due to CH2 and CH protons, respectively. It
showed also two D2O-exchangeable signals at δ 7.80 and 9.10 due to two NH protons, in addition to an
aromatic multiplet in the region 7.22-7.73. Compound 5 couples smoothly with diazotized
4-methylaniline to afford 4-phenyl-8-(phenylsulfonyl)-6-(p-tolyl)-3,4-dihydropyrimido-[4,5-d]pyridazine-
2,5-(1H,6H)-dione (7) (Scheme 1). The IR spectrum of pyrimido[4,5-d]pyridazine 7 showed absorption
bands at 1663, 1720, 3105 and 3387 cm-1 corresponding to two carbonyl groups and two imino functions,
respectively. Its 1H NMR spectrum revealed the absence of CH3 and CH2 protons of ethoxycarbonyl group
and showed signals at δ 5.43 due to CH proton. It showed also two D2O-exchangeable signals at δ 7.25 and
8.32 due to two NH protons, in addition to an aromatic multiplet in the region 7.31-8.07.
O
Me
NH
Br
Ph
O
O
O
S
EtO
Ph
Br2
PhSO2Na
EtO
Ph
NH
HN
O
N
H
O
N
H
O
O
HN
OEt
Ph
5
1
3
ArN2Cl
Ar
HN
O
O
S
HN
Ph
N
Ph
NH
EtO
EtOH
O
O
NH
O
S Ph
O
O
N N
Ph
N
O
Ar
H
7
Ar = 4-MeC6H4
6
Scheme 1
Bromination of ethyl 6-methyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (2) in acetic acid,
afforded the corresponding 6-bromomethyl derivative 4 (Scheme 2). Treatment of the latter compound
with sodium benzenesulfinate afforded the corresponding ethyl 2-oxo-4-phenyl-6-(phenylsulfonylmethyl)
-1,2-dihydropyrimidine-5-carboxylate (8) (Scheme 2). The IR spectrum of the product 8 revealed
absorption bands at 1647, 1705 and 3337 cm-1 corresponding to two carbonyl groups, and two imino

HETEROCYCLES, Vol. 78, No. 4, 2009
939
1
functions, respectively. Its H NMR spectrum showed a triplet signal at δ 0.99 (J = 7.5 Hz) due to CH3
protons and a quartet signal at δ 3.74 (J = 7.5 Hz) due to CH2 protons, and a singlet signal at δ 4.83 due to
CH2 protons. It showed also D2O-exchangeable signal at δ 9.1 due to NH proton, in addition to an
aromatic multiplet in the region 7.24-7.73
O
Ph
Br
S
O
Me
NH
O
O
Br2
O
PhSO2Na
EtO
Ph
EtO
Ph
NH
EtO
NH
N
O
N
O
Ph
N
O
2
4
8
Scheme 2
Treatment of 6-bromomethylpyrimidine 4 with malononitrile and with ethyl cyanoacetate afforded the
corresponding ethyl 7-amino-6-cyano-1,2-dihydro-1-oxo-3-phenylpyrrolo[1,2-c]pyrimidine-4-
carboxylate (11a) and 4,6-diethyl 7-amino-1,2-dihydro-1-oxo-3-phenylpyrrolo[1,2-c]pyrimidine-4,6-
dicarboxylate (11b), respectively (Scheme 3). The IR spectrum of compound 11b, taken as a typical
example of the prepared compounds, exhibited absorption bands at 1675, 1715, 1720, 3280-3320 and
3445 cm-1 corresponding to three carbonyl groups, amino and imino functions, respectively. Its 1H NMR
spectrum revealed signals at δ 0.83, 1.27, 3.93, 4.19 and 6.43 due to two ethoxycarbonyl and CH protons,
respectively. It showed also D2O-exchangeable signals at δ 6.84 and 10.92 corresponding to NH2 and NH
protons, respectively, in addition to an aromatic multiplet in the region δ 7.34-7.44. Its mass spectrum
revealed a molecular ion peak at m/z 369.
Reaction of the 6-bromomethyl derivative 4 with thiosemicarbazide afforded ethyl 3-hydrazono-5,6-
dihydro-5-oxo-7-phenyl-3H-thiazolo[3,4-c]pyrimidine-8-carboxylate (14) (Scheme 4). The IR spectrum
of the product 14 revealed absorption bands at 1675, 1735 and 3225-3195 corresponding to two carbonyl
groups, amino and imino functions, respectively. Its 1H NMR spectrum showed a triplet signal at δ 0.9 (J
= 7.2 Hz) due to CH3 protons, a quartet signal at δ 4.03 (J = 7.2 Hz) due to CH2 protons, two D2O-
exchangeable signals at δ 8.66 and 12.05 due NH2 and NH protons, respectively, in addition to an
aromatic multiplet in the region δ 7.49-7.53.
The above reaction is assumed to proceed via nucleophilic substitution of bromine atom in compound 4
by thiosemicarbazide moiety to afford the acyclic intermediate 13 which underwent intramolecular
cyclocondensation through elimination of ammonia molecule to afford the final product 14 as shown in
Scheme 4.
Similarly, nucleophilic substitution reaction of bromine atom in 6-bromomethyl derivative 4 with
hydrazine hydrate and with phenylhydrazine, afforded ethyl 6-hydrazinomethyl-2-oxo-4-phenyl-1,2-
dihydropyrimidine-5-carboxylate (15a) and ethyl 2-oxo-4-phenyl-6-((2-phenylhydrazinyl)methyl)-1,2-

940
HETEROCYCLES, Vol. 78, No. 4, 2009
dihydropyrimidine-5-carboxylate (15b), respectively (Scheme 4). The IR spectrum of compound 15b,
taken as a typical example of the prepared compounds, revealed absorption bands at 1670, 1718, 3010,
1
3120, 3285 cm-1 corresponding to two carbonyl groups, and three imino functions, respectively. Its H
NMR spectrum showed a triplet signal at δ 0.86 (J = 7.2 Hz) due to CH3 protons, a singlet signal at δ 3.35
(J = 7.2 Hz) due to CH2 protons, a quartet signal at δ 3.95 due to CH2 protons and three D2O-
exchangeable signal at δ 7.84, 11.61, 11.90 corresponding to three NH protons, in addition to an aromatic
multiplet in the region δ 6.91-7.55.
O
Ph
EtO
Br
N
NC
X
N
H
O
4
O
Ph
Ph
O
EtO
NC
N
NC
X
-EtOH
N
N
H
O
N
H
O
X
12a,b
9a,b
O
X
Ph
O
Ph
N
EtO
N
EtO
NH
H
O
N
O
H
NH2
NH2
11a,b a, X = CN
b, X = CO2Et
X
10a,b
Scheme 3
Heating of compounds 15a and 15b in ethyl acetoacetate led to the formation of products identified as 4-
phenylpyrimido[4,5-d]pyridazine-2,5-(1H,6H)-dione (17a) and 4,6-diphenyl-1H-pyrimido[4,5-
d]pyridazine-2,5-(1H,6H)dione (17b), respectively, instead of the expected pyrazolone structures 18a and
18b, respectively (Scheme 4). The IR spectrum of compound 17a, revealed absorption bands at 1659,
1
1690, 3040 and 3220 cm-1 corresponding to two carbonyl, and two imino functions, respectively. Its H
NMR spectrum revealed the disappearance of the signal corresponding to CH3 and CH2 protons of ethoxy
group and showed two D2O-exchangeable signals at δ 7.94 and 12.87 corresponding to two NH protons,
in addition to an aromatic multiplet in the region δ 7.38-7.56. Compounds 17a and 17b are assumed to be
formed through intramolecular cyclization of compounds 15a and 15b via loss of EtOH molecule under
the reaction conditions (a high boiling solvent) followed by dehydrogenation to afford the final products
17a,b as shown in Scheme 4.

HETEROCYCLES, Vol. 78, No. 4, 2009
941
Ph
O
S
RNHNH2
EtO
Br
N
H2N
NHNH2
Ph
O
N
H
4
O
Ph
N
O
EtO
H
N
EtO
RHNHN
O
N
H
NH2
N
H
O
H
S
15a,b
∆
NNH2
13
EAA/
-EtOH
- NH3
Ph
O
Ph
O
R
O
Ph
N
N
EtO
NH
EtO
HN
N
H
16a,b
O
O
N
N
S
N
H
O
R
NNH2
O
N
N
-H2
14
18a,b
O
Ph
Me
R
N
N
N
a, R = H
b, R = Ph
N
H
O
17a,b
Scheme 4
The 1,2-dihydropyrimidine 2 couples smoothly with 4-methylbenzene diazonium chloride to afford the
corresponding 6-(4-methylphenyl)-8-(4-methylphenylazo)-4-phenyl-1H-pyrimido[4,5-d]pyridazine-2,5-
(1H,6H)-dione (20) (Scheme 5). The IR spectrum of compound 20 exhibited absorption bands at 1650,
1
1675 and 3245 cm-1 corresponding to two carbonyl groups and an imino function, respectively. Its H
NMR spectrum revealed a singlet signal at δ 2.35 due to CH3 protons and D2O-exchangeable signal at δ
10.72 due to NH proton, in addition to an aromatic multiplet in the region 7.31-7.66. Also, its mass
spectrum revealed a molecular ion peak at m/z 448.
O
Ph
O
Ph
ArN2Cl
2
EtO
N
N
EtO
Me
N
N
H
O
ArHN
C
N
N
H
NAr
O
2
19
- EtOH
Ph
O
Ar
N
N
NH
N
O
N
20, Ar = 4-MeC6H4
N
Ar
Scheme 5

942
HETEROCYCLES, Vol. 78, No. 4, 2009
The above reaction is assumed to take place by coupling of the diazonium salt at an active methyl group
in compound 2 and formation of the formazan-type22,23 intermediate 19 which undergwent intramolecular
cyclocondensation via loss of ethanol molecule, under the reaction conditions, to afford the final product
20 as shown in Scheme 5.
EXPERIMENTAL
All melting points were measured on a Gallenkamp melting point apparatus. The infrared spectra were
recorded in potassium bromide disks on a pye Unicam SP 3300 and Shimadzu FT IR 8101 PC infrared
spectrophotometers. The NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer.
1H spectra were run at 300 MHz and 13C spectra were run at 75.46 MHz in dimethyl sulphoxide
(DMSO-d6). Chemical shifts were related to that of the solvent. Mass spectra were recorded on a
Shimadzu GCMS-QP 1000 EX mass spectrometer at 70 e.V. Elemental analyses (C, H, N, S) were
carried out at the Microanalytical Center of Cairo University, Giza, Egypt. Ethyl
6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1),20 ethyl 6-methyl-2-oxo-4-
phenyl-1,2-dihydropyrimidine-5-carboxylate (2)21 and ethyl 6-bromomethyl-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (3)19 were prepared following the literature procedure.
Ethyl 6-bromomethyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (4).
To a solution of the 1,2-dihydropyrimidine 2 (2.58 g, 10 mmol) in acetic acid (20 mL), bromine (0.52 mL,
10 mmol) in acetic acid (12 mL) was added portion-wise at 40-50 ºC for 1 h, then the resulting mixture
was poured onto cold water. The precipitated solid was collected by filtration, washed with water, dried
and finally crystallized from EtOH afforded white crystals (72% yield), mp 170-171 oC (EtOH); IR (KBr)
ν 3280 (NH), 1718 (C=O), 1665 (C=O) cm-1; 1H NMR (CDC13) δ 0.87 (t, 3H, CH3, J = 6.9 Hz), 4.0 (q,
2H, CH2, J = 6.9 Hz), 4.54 (s, 2H, CH2), 7.40-7.57 (m, 5H, ArH), 9.6 (s, 1H, D2O-exchangeable NH); MS
m/z (%) 338 (12.9), 337 (6.4), 336 (7.2), 291 (14.3), 257 (100.0), 229 (83.8), 184 (12.9), 140 (10.3), 104
(39.4). Anal. Calcd for C14H13O3N2Br: C, 49.87; H, 3.89; N, 8.31. Found: C, 49.90; H, 3.86; N, 8.28%.
Synthesis of 6-(phenylsulfonylmethyl)pyrimidine 5 and 8.
General procedure
A solution of the appropriate 6-bromomethylpyrimidine derivatives 3 or 4 (1 mmol) in EtOH 10 mL and
sodium benzenesulfinate (0.164 g, 1 mmol) was heated under reflux for 1 h then left to cool. The resulting
mixture was diluted with water (3 mL). The solid precipitate was filtered off, washed with water and
dried. Recrystallization from the EtOH give the corresponding 6-(phenylsulfonylmethyl)pyrimidine
derivatives 5 and 8, respectively,
Ethyl 2-oxo-4-phenyl-6-(phenylsulfonylmethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (5). Yield
(71%), mp 234-5 ºC; IR (KBr) ν 3337 (NH), 3113 (NH), 1705 (C=O), 1647 (C=O) cm-1; 1H NMR

HETEROCYCLES, Vol. 78, No. 4, 2009
943
(DMSO-d6) δ 1.00 (t, 3H, CH3, J = 7.5 Hz), 3.73 (q, 2H, CH2, J = 7.5 Hz), 4.94 (s, 2H, CH2), 5.12 (d, 1H,
CH, J = 2.7 Hz), 7.22-7.73 (m, 10H, ArH’s), 7.80 (s, 1H, D2O-exchangeable, NH), 9.10 (s, 1H,
13
D2O-exchangeable, NH); C NMR (DMSO-d6): δ 13.68, 54.06, 55.71, 59.73, 104.32, 126.24, 127.51,
128.13, 128.37, 128.98, 133.97, 137.81, 138.25, 143.72, 151.74, 164.09. Anal. Calcd for C20H20O5N2S: C,
59.99; H, 5.03; N, 7.00. Found: C, 59.97; H, 5.00; N, 7.03%.
Ethyl 2-oxo-4-phenyl-6-(phenylsulfonylmethyl)-1,2-dihydropyrimidine-5-carboxylate (8).
Yield (73%), mp 232-3 ºC; IR (KBr) ν 3337 (NH), 1705 (C=O), 1647 (C=O) cm-1; 1H NMR (DMSO-d6)
δ 0.99 (t, 3H, CH3, J = 7.5 Hz), 3.74 (q, 2H, CH2, J = 7.5 Hz), 4.83 (s, 2H, CH2), 7.24-7.73 (m, 10H,
ArH’s), 9.1 (s, 1H, D2O-exchangeable, NH). MS m/z (%) 402 (7.0), 401 (9.4), 400 (4.9), 356 (7.8), 355
(12.3), 141 (10.2), 77 (100.0). Anal. Calcd for C20H18O5N2S: C, 60.29; H, 4.55; N, 7.03. Found: C, 60.32;
H, 4.58; N, 7.05%.
4-Phenyl-8-(phenylsulfonyl)-6-(p-tolyl)-3,4-dihydropyrimido[4,5-d]pyridazine-2,5-(1H,6H)-dione (7).
To a cold solution of the pyrimidine derivative 5 (0.4 g, 1 mmol) in pyridine (5 mL) was added an
equimolar amount of 4-methylbenzene diazonium chloride [prepared by diazotizing 4-methylaniline
(0.107 g, 1 mmol) in hydrochloric acid (6 M, 0.3 mL) with sodium nitrite solution (0.07 g, 1 mmol, in 1
mL water). The addition was carried out portion-wise with stirring at 0-5 ºC over a period of 30 min.
After complete addition the reaction mixture was stirred for further 4 h then kept in an ice chest for 12 h.
The precipitated solid was collected by filtration, washed with water, dried and finally recrystallized from
EtOH to afford the 4-phenyl-8-(phenylsulfonyl)-6-(p-tolyl)-3,4-dihydropyrimido[4,5-d]pyridazine-2,5-
(1H,6H)-dione (7) in 75 %yield. mp 244-5 ºC; IR (KBr) ν 3387 (NH), 3213 (NH), 1720 (C=O), 1663
(C=O) cm-1; 1H NMR (DMSO-d6) δ 2.33 (s, 3H, CH3), 5.43 (d, 1H, CH, J = 2.7 Hz), 7.25 (s, 1H,
D2O-exchangeable, NH), 7.31-8.07 (m, 14H, ArH’s), 8.32 (s, 1H, D2O-exchangeable, NH). Anal. Calcd
for C25H20O4N4S: C, 63.55; H, 4.27; N, 11.86. Found: C, 63.57; H, 4.30; N, 11.88%.
Reaction of 6-bromomethylpyrimidine derivative 4 with malononitrile and ethyl cyanoacetate.
General procedure
To a solution of 4 (0.34 g, 1 mmol) and malononitrile (0.066 g, 1 mmol) or ethyl cyanoacetate (0.113 mL,
1 mmol) in EtOH (20 mL) was added few drops of piperidine and the reaction mixture was refluxed for 4
h then left to cool. The formed solid product was collected by filtration, washed with EtOH and purified
by crystallization from the appropriate solvent to afford the corresponding pyrrolo[1,2-c]pyrimidine
derivatives 11a and 11b, respectively.
Ethyl 7-amino-6-cyano-1,2-dihydro-1-oxo-3-phenylpyrrolo[1,2-c]pyrimidine-4-carboxylate (11a). Yield
(79%), mp > 300 oC (DMF); IR (KBr) ν 3441 (NH), 3317-3240 (NH) and NH2, 2120 (C≡N), 1728 (C=O),
1697 (C=O) cm-1; 1H NMR (DMSO-d6) δ 0.87 (t, 3H, CH3, J = 7.2 Hz), 3.94 (q, 2H, CH2, J = 7.2 Hz),
6.38 (s,1H, CH), 7.33-7.46 (m, 5H, ArH), 7.04 (s, 2H, D2O-exchangeable NH2), 11.06 (s,1H,

944
HETEROCYCLES, Vol. 78, No. 4, 2009
13
D2O-exchangeable NH); C NMR (DMSO-d6): δ 14.60, 61.12, 102.53,102.78, 116.38, 120.78, 120.82,
127.79, 128.35, 128.45, 130.57, 133.33, 147.90, 152.36, 163.81; MS m/z (%) 325 (2.3), 323 (73.7), 322
(M+, 100.0), 321 (6.2), 295 (12.0). Anal. Calcd for C17H14O3N4: C, 63.35; H, 4.38; N, 17.38. Found: C,
63.40; H, 4.36; N, 17.35%.
Diethyl 7-amino-1,2-dihydro-1-oxo-3-phenylpyrrolo[1,2-c]pyrimidine-4,6-carboxylate (11b). Yield
(61%), mp 225-226 oC (EtOH/ DMF); IR (KBr) ν 3445 (NH), 3320-3280 (NH) and NH2, 1720 (C=O),
1715 (C=O), 1675 (C=O cm-1; 1H NMR (DMSO- d6) δ 0.83 (t, 3H, CH3, J = 6.9 Hz), 1.27 (t, 3H, CH3, J
= 6.9 Hz), 3.93 (q, 2H, CH2, J = 6.9 Hz), 4.19 (q, 2H, CH2, J = 6.9 Hz), 6.43 (s, 1H, CH), 6.84 (s, 2H,
D2O-exchangeable NH2), 7.34-7.44 (m, 5H, ArH), 10.92 (s, 1H, D2O-exchangeable NH); 13C NMR
(DMSO-d6): δ 13.29, 14.46, 58.97, 60.33, 94.20, 101.67, 103.33, 120.02, 127.96, 128.47, 129.04, 133.55,
137.51, 144.85, 148.32, 164.19, 164.59; MS m/z (%) 371 (4.3), 370 (21.3), 369 (M+, 100), 323 (62.1),
297 (1.5), 266 (73.2), 104 (17.6). Anal. Calcd for C19H19O5N3: C, 61.78; H, 5.18; N, 11.38. Found: C,
61.76; H, 5.15; N, 11.41%.
Ethyl 3-hydrazono-5,6-dihydro-5-oxo-7-phenyl-3H-thiazolo[3,4-c]pyrimidine-8-carboxylate (14).
To a solution of 4 (0.337 g, 1 mmol) in EtOH (20 mL), and thiosemicarbazide (0.92 g, 1 mmol) was
added and the reaction mixture was refluxed for 4 h, and then allowed to cool. The solid product was
collected by filtration, washed with EtOH and crystallized from DMF/EtOH to afford 14 in 63% yield,
o
1
mp 285-287 C (DMF); IR (KBr) ν 3380 (NH), 3225-3195 (NH2), 1735 (C=O), 1675 (C=O) cm-1; H
NMR (DMSO- d6) δ 0.90 (t, 3H, CH3, J = 7.2 Hz), 4.03 (q, 2H, CH2, J = 7.2 Hz), 7.49-7.53 (m, 5H, ArH),
8.12 (s, 1H, CH), 8.66 (s, 1H, D2O-exchangeable NH), 12.05 (s, 2H, D2O-exchangeable NH2); 13C NMR
(DMSO-d6): δ 13.27, 61.58, 109.45, 120.87, 127.42, 128.28, 129.61, 130.36, 138.08, 154.63, 165.01,
172.40, 179.14. Anal. Calcd for C15H14O3N4S: C, 54.53; H, 4.27; N, 16.96. Found: C, 54.56; H, 4.32; N,
16.87%.
Reaction of 4 with hydrazine derivatives.
General procedure:
To a solution of 4 (0.674 g, 2 mmol) in EtOH (20 mL), and hydrazine hydrate (80%, 0.2 mL, 2 mmol) or
with phenylhydrazine (0.216 g, 2 mmol) was added and the reaction mixture was refluxed for 4 h, and
then allowed to cool. The formed solid product was collected by filtration, washed with EtOH and
crystallised from EtOH/DMF to afford compounds 15a and 15b, respectively.
Ethyl 6-hydrazinomethyl-2-oxo-4-phenyl-1,2-dihydropyrimidine-5-carboxylate (15a). Yield (71%), mp
o
235-236 C (EtOH/DMF); IR (KBr) ν 3320 (NH), 3275 (NH), 3100 (NH2), 1725 (C=O), 1655 (C=O)
cm-1; 1H NMR (DMSO- d6) δ 0.85 (t, 3H, CH3, J = 6.9 Hz), 3.8 (q, 2H, CH2, J = 6.9 Hz), 4.07 (s, 2H,
CH2), 7.19-7.45 (m, 5H, PhH), 8.78 (s, 2H, D2O-exchangeable NH2), 10.87 (s, 1H, D2O-exchangeable
NH), 11.72 (s, 1H, D2O-exchangeable NH); MS m/z (%) 288 (M+, 18.1), 272 (100.0), 244 (11.0), 180

HETEROCYCLES, Vol. 78, No. 4, 2009
945
(12.9), 141 (14.7), 77 (48.9). Anal. Calcd for C14H16O3N4: C, 58.32; H, 5.59; N, 19.43. Found: C, 58.28;
H, 5.57; N, 19.39%.
Ethyl 2-oxo-4-phenyl-6-((2-phenylhydrazinyl)methyl)-1,2-dihydropyrimidine-5-carboxylate (15b). Yield
o
(79%), mp 220-221 C (EtOH); IR (KBr) ν 3285 (NH), 3120 (NH), 1718 (C=O), 1670 (C=O). cm-1; 1H
NMR (DMSO-d6) δ 0.86 (t, 3H, CH3, J = 7.2 Hz), 3.35 (s, 2H, CH2), 3.95 (q, 2H, CH2, J = 7.2 Hz),
6.91-7.55 (m, 10H, Ar H), 7.84 (s, 1H, D2O- exchangeable NH), 11.61 (s, 1H, D2O-exchangeable NH),
11.9 (s, 1H, D2O-exchangeable NH); 13C NMR (DMSO-d6): δ 13.25, 40.33, 52.64, 61.02, 88.95, 107.33,
113.82, 121.67, 127.54, 128.18, 129.07, 130.62, 132.16, 143.14, 155.61, 165.96; MS m/z (%) 364 (M+,
5.2), 363 (32.3), 315 (47.1), 229 (60.9), 171 (16.5), 77 (100.0). Anal. Calcd for C20H20O3N4: C, 65.92; H,
5.53; N, 15.38. Found: C, 65.87; H, 5.48; N, 15.40%.
Synthesis of pyrimido[4,5-d]pyridazine derivatives 17a and 17b.
General procedure:
A solution of 15a or 15b (0.728 g, 2 mmol) in ethyl acetoacetate (5.0 mL) was refluxed for 3h, then left to
cool to rt. The precipitated solid was collected by filtration, washed with EtOH and crystallized from
DMF/EtOH to afford 17a and 17b, respectively.
o
4-Phenylpyrimido[4,5-d]pyridazine-2,5-(1H,6H)-dione (17a).Yield (84%), mp >300 C; IR (KBr) ν
3220 (NH), 3040 (NH), 1690 (C=O), 1659 (C=O) cm-1; 1H NMR (DMSO- d6) δ 7.38-7.56 (m, 6H, ArH),
7.94 (s, 1H, D2O-exchangeable NH), 12.87 (s, 1H, D2O-exchangeable NH). Anal. Calcd for C12H8O2N4:
C, 60.00; H, 3.36; N, 23.32. Found: C, 60.09; H, 3.32; N, 23.30%.
4,6-Diphenyl-1H-pyrimido[4,5-d]pyridazine-2,5-(1H,6H)-dione (17b).Yield (79%), mp 295-297 oC
(DMF); IR (KBr) ν 3220 (NH), 1695 (C=O), 1670 (C=O) cm-1; 1H NMR (DMSO- d6) δ 7.38-7.85 (m,
13
10H, ArH), 8.14 (s, 1H, CH), 12.74 (s, 1H, D2O-exchangeable NH); C NMR (DMSO-d6): δ 106.53,
121.56, 125.95, 127.16, 127.95, 128.19, 128.52, 128.65, 129.07, 129.85, 137.83, 141.21, 155.78, 164.72;
MS m/z (%) 316 (M+, 99.5), 315 (55.6), 156 (28.9), 91 (18.7), 78 (13.9), 77 (100.0). Anal. Calcd for
C18H12O2N4: C, 68.35; H, 3.82; N, 17.71. Found: C, 68.32; H, 3.80; N, 17.74%.
6-(4-Methylphenyl)-8-(4-methylphenylazo)-4-phenyl-1H-pyrimido[4,5-d]pyridazine-2,5(1H,6H)-dione
(20).
To a cold solution of the pyrimidone 2 (2.85 g, 10 mmol) in ethanol (50 mL) and sodium acetate
trihydrate (3 g) was added equimolar amount of 4-methylbenzene diazonium chloride [prepared by
diazotizing 4-methylaniline (1.07 g, 10 mmol) in hydrochloric acid (6 M, 3 mL) with sodium nitrite
solution (0.7 g, 10 mmol in 5 mL water). The addition was carried out portion-wise with stirring at 0-5 ºC
over a period of 30 min. After complete addition, the reaction mixture was stirred for further 4 h then kept
in an ice chest for 12 h and finally diluted with water. The precipitated solid was collected by filtration,
washed with water, dried and finally crystallized from DMF to afford red crystals of 20. Yield (71%); mp

946
HETEROCYCLES, Vol. 78, No. 4, 2009
o
> 300 C (DMF); IR (KBr) ν 3245 (NH), 1675 (C=O), 1650 cm-1 (C=O) cm-1; 1H NMR (DMSO- d6) δ
2.35 (s, 6H, 2CH3), 7.31-7.66 (m, 13H, Ar′ H), 10.72 (s, 1H, D2O-exchangeable NH); MS m/z (%) 448
(M+, 10.4), 391 (9.5), 345 (23.2), 242 (7.0), 106 (100.0), 101 (2.8), 77 (28.4). Anal. Calcd for
C26H20O2N6: C, 69.63; H, 4.49; N, 18.74. Found: C, 69.59; H, 4.49; N, 18.71%.
REFERENCES
1. C. O. Kappe, Eur. J. Med. Chem., 2000, 35, 1043.
2. W. Schuett and H. Raoooort, J. Am. Chem. Soc., 1962, 84. 2266.
3. W. J. Coates, US Patent 5162316, 1992.
4. R. E. Hackler and G. P. Jourdan, US Patent 5034393, 1991.
5. F. Himmelsbach and T. Von Ruden, US Patent 5707989, 1998.
6. N. A. Khedr, Y. N. Mabkhot, and A. M. Farag, Heterocycles, 2008, 75, 887.
7. N. A. Khedr, Y. N. Mabkhot, and A. M. Farag, Synth. Commun., 2008, 38, 3170.
8. M. R. Shaaban, T. S. Saleh, A. S. Mayhoub, A. Mansour, and A. M. Farag, Bioorg. Med. Chem.,
2008, 16, 6344.
9. A. M. Farag, A. S. Mayhoub, S. E. Barakat, and A. H. Bayomi, Bioorg. Med. Chem., 2008, 16, 4569.
10. A. M. Farag, A. S. Mayhoub, S. E Barakat, and A. H. Bayomi, Bioorg. Med. Chem., 2008, 16, 881.
11. A. S. Girgis, N. Mishriky, A. M. Farag, W. I. El-Eraky, and H. Farag, Eur. J. Med. Chem., 2008, 43,
1818.
12. A. M. Farag, Y. M. Elkholy, and K. A. Ali, J. Heterocycl. Chem., 2008, 45, 279.
13. N. A. Khedr, Y. N. Mabkhot, and A. M. Farag, Heterocycles, 2008, 75, 2937.
14. K. M. Dawood, A. M. Farag, and N. A. Khedr, Arkivoc, 2008, XV, 166.
15. M. R. Shaaban, T. S. Saleh, and A. M. Farag, Heterocycles, 2009, 78, 151.
16. M. R. Shaaban, T. S. Saleh, and A. M. Farag, Heterocycles, 2009, 78, 699.
17. M. R. Shaaban, T. S. Saleh, and A. M. Farag, Heterocycles, 2007, 71, 1765.
18. A. M. Farag, K. M. Dawood, and N. A. Khedr, J. Chem. Res., 2007, 472.
19. G. Zigeuner, H. Hamberger, H. Blaschke, and H. Sterk, Monatsh. Chem., 1966, 97, 1408.
20. P. Biginelli, Gazz. Chim. Ital., 1893, 23, 360.
21. A. Puchala, F. Belaj, J. Bergman, and C. O. Kappe, J. Heterocycl. Chem., 2001, 38, 1345.
22. G. T. Pilyugin, S. V. Shinkorenko, O. M. Stashkevich, and V. V. Stashkevich, Khim. Geterotsikl.
Soedin., 1966, 2, 406. (Chem. Abstr., 1966, 65, 18726a).
23. I. Szele and H. Zollinger, "Azo coupling reactions structures and mechanisms", Top. Curr. Chem.
(Springer), 1983, 112, 15.